The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Genentech
KEYlargo: A phase II study of first-line pembrolizumab (P), capecitabine (C), and oxaliplatin (O) in HER2-negative gastroesophageal (GE) adenocarcinoma.
 
Hope Elizabeth Uronis
Employment - GeneCentric (I)
Stock and Other Ownership Interests - GeneCentric (I)
Consulting or Advisory Role - Bristol-Myers Squibb
Research Funding - Advaxis (Inst); Bristol-Myers Squibb (Inst); Dekkun Corporation (Inst); Genentech/Roche (Inst); Lycera (Inst); Macrogenics (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Christel Rushing
No Relationships to Disclose
 
Gerard C. Blobe
No Relationships to Disclose
 
Shiaowen David Hsu
Stock and Other Ownership Interests - AccuBeing; Xilis
Research Funding - Amgen
 
Niharika B. Mettu
Research Funding - Amgen (Inst); Amphivena (Inst); BioMed Valley Discoveries (Inst); Bristol-Myers Squibb (Inst); ERYTECH Pharma (Inst); Genentech (Inst); Incyte (Inst); Lucence Diagnostics (Inst); MedImmune (Inst); Repare Therapeutics (Inst)
Travel, Accommodations, Expenses - Genentech
 
James Leroy Wells
No Relationships to Disclose
 
Donna Niedzwiecki
No Relationships to Disclose
 
Leighanne Hartman
No Relationships to Disclose
 
Ashley Moyer
Employment - Almac Group (I)
 
Herbert I. Hurwitz
No Relationships to Disclose
 
John H. Strickler
Consulting or Advisory Role - Abbvie; Amgen; Bayer; Chengdu Kanghong Biotech; Genentech/Roche; Mereo Biopharma; Natera (Inst); OncoMed; Pfizer; Proteus Digital Health; Seagen (Inst)
Research Funding - A*STAR (Inst); Abbvie (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Curegenix (Inst); Exelixis (Inst); Gilead Sciences (Inst); Leap Therapeutics (Inst); Macrogenics (Inst); Nektar (Inst); OncoMed (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Seagen